Pharmaceuticals

Competitive and Market Trend Analysis of Biobetters Industry Through 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Biobetters Industry?#_x000D_

The significant expansion of the respiratory biologics market in the past few years has been notable. It is projected to increase from a market worth of $6.38 billion in 2024 to $7.41 billion in 2025, with a compound annual growth rate (CAGR) of 16.1%. The historical growth of this market can be credited to factors like the escalating occurrence of respiratory conditions, an increase in the adoption of personalized medicine, a surge in global healthcare expenditure, increased awareness and diagnosis rates of respiratory diseases, as well as a rising geriatric populace suffering from respiratory issues._x000D_

_x000D_

In the coming years, the respiratory biologics market size is projected to undergo swift expansion and is expected to reach “$13.51 billion in 2029 with a compound annual growth rate (CAGR) of 16.2%. The expected growth during the predicted period can be linked to the growing cases of asthma and COPD, increasing utilization of biologic therapies, rise in R&D expenditures, growing need for non-invasive medicine delivery, and widening of reimbursement policies. Noteworthy trends during this prediction period are expected to involve application of monoclonal antibodies in treating respiratory disorders, progress in formulations and delivery techniques of biologic drugs, regulatory clearances, tactical alliances and takeovers amongst influential players, and the merging of artificial intelligence in pharmaceutical research and production._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Biobetters Industry?#_x000D_

The biobetters market is predicted to expand as a result of an increasing number of chronic kidney disease (CKD) cases. CKD is characterized as a progressive ailment that disrupts and eventually halts kidney function. Factors such as an aging population, a rise in diabetes and hypertension cases, unhealthy diet, lack of physical activity, environmental contamination, and advanced diagnostic tools are contributing to the upsurge in CKD prevalence. Biobetters offer substantial benefits in managing CKD, providing superior efficacy, lesser side effects, convenient dosage schedules, and improved stability than the original biologic medicines, ultimately leading to enhanced patient outcomes. As a case in point, data from Oxford Academic, a research platform of Oxford University Press based in the UK, indicates that CKD prevalence in the UK is predicted to increase by 4% from 8.27 million to 8.61 million individuals from 2022 to 2032. The stage distribution in 2032 is anticipated at 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Hence, the escalating cases of chronic kidney diseases are propelling the growth of the biobetters market._x000D_

_x000D_

The respiratory biologics market covered in this report is segmented – _x000D_

_x000D_

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome_x000D_

2) By Route Of Administration: Intravenous, Subcuteneous_x000D_

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma_x000D_

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps_x000D_

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES_x000D_

_x000D_

#How Are Key Trends Driving Expansion In The Biobetters Industry?#_x000D_

Leading firms in the respiratory biologics market are prioritizing the development of cutting-edge biologic remedies. These include targeted immune therapies for chronic respiratory illnesses that can minimize inflammation and enhance lung functionality. These therapies work by managing the body’s immune system, reducing swelling, and alleviating breathing difficulties in long-term lung diseases. A case in point is the France-based pharmaceutical giant Sanofi S.A., which, in September 2024, received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab). The drug, intended as an additional maintenance therapy for adults with poorly controlled chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype, made history as Dupixent turned out to be the first biologic drug sanctioned in the US for this particular COPD patient cohort._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Biobetters Market?#_x000D_

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc. _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Biobetters Market Through 2029?#_x000D_

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_